mProX™ Human CD33 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD33 is a protein that has been studied in various applications. In the context of neuroinflammation and Alzheimer's disease (AD), CD33 has been identified as a potential risk factor for neuroinflammation. It is involved in the upregulation of proinflammatory factors and contributes to the accumulation of toxic tau and amyloid-beta in the brain. CD33 is also associated with the homeostasis of synaptic transmission and its remodeling by pruning. In the field of hematopoietic stem/progenitor cell (HSPC) transplantation, CD33 has been targeted for deletion or modification to protect normal HSPCs from unwanted toxicities. Studies have shown efficient long-term engraftment of CD33-edited HSPCs in nonhuman primates without adverse effects on their functionality. Additionally, CD33 has been investigated in the diagnosis of chronic myeloid leukemia (CML) using flow cytometry. It has been found that CD33 expression is increased in CML patients, along with other markers, providing insights for the diagnosis of the disease. Furthermore, CD33 has been implicated in the interplay of hematological parameters, CD markers, genetic polymorphisms, and database mutations in acute myeloid leukemia (AML) patients. The expression of CD33 and other markers was found to be upregulated in AML patients, and mutations in the IL15 gene, which is associated with AML, were identified. Overall, CD33 has diverse applications in the fields of neuroinflammation, HSPC transplantation, and the diagnosis and understanding of leukemia.